SCHEMBL1634396

SCHEMBL1634396

CC(C)N1CCC(Oc2cccc3cnc(Nc4cccc(F)c4)nc23)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.53
JAK1 P23458 3/20 0.53
TYK2 P29597 3/20 0.53
JAK3 P52333 3/20 0.53
TNIK Q9UKE5 1/20 0.50
ALK Q9UM73 1/20 0.42
NTRK1 P04629 1/20 0.41
SCN9A Q15858 5/20 0.41
CDK4 P11802 2/20 0.41
CCND1 P24385 2/20 0.41
CCND2 P30279 1/20 0.41
CCND3 P30281 1/20 0.41
SCN8A Q9UQD0 1/20 0.40
MAPK10 P53779 1/20 0.40
EGFR P00533 2/20 0.38
ITK Q08881 2/20 0.38
GRM5 P41594 1/20 0.38
BTK Q06187 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633185 0.93 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633043 0.91 JAK2 (0.55) JAK2JAK1TYK2JAK3TNIK
SCHEMBL13498290 0.90 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634187 0.89 JAK2 (0.57) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632698 0.89 JAK2 (0.53) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632878 0.89 JAK2 (0.53) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634707 0.88 JAK2 (0.51) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633160 0.86 JAK1 (0.52) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633691 0.86 JAK2 (0.51) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1633164 0.86 JAK2 (0.54) JAK2JAK1TYK2JAK3TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 JAK2 1352/4885JAK1 2248/4885TYK2 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.